Mitogen-activated protein kinase 4 (MAPK4)

Mitogen-activated protein kinase 4 is an atypical member of the MAPK family, distinct from classical MAPKs, as it lacks the canonical Thr-X-Tyr activation motif and is activated by noncanonical mechanisms[5]. MAPK4 directly phosphorylates AKT at threonine 308 and promotes mTORC2-mediated serine 473 phosphorylation, driving cell survival, proliferation, and migration in a PI3K-independent manner[2][3]. It has emerged as an oncogenic regulator in several cancers, with its overexpression correlating with poor prognosis and aggressive disease phenotypes[5][6]. MAPK4 may serve as both a prognostic biomarker and a potential therapeutic target for novel cancer treatment strategies[3][5][6].

Other names

ERK4P63MAPKPRKM4P63-MAPK

Drugs targeting MAPK4 would likely inhibit its kinase activity, thereby suppressing downstream AKT/mTOR pathway activation[2][5]. Potential mechanisms could include ATP-competitive inhibition, blocking substrate binding, and interfering with MAPK4 protein-protein interactions[2].